381 related articles for article (PubMed ID: 31784932)
1. Platelet Function in Cardiovascular Disease: Activation of Molecules and Activation by Molecules.
Khodadi E
Cardiovasc Toxicol; 2020 Feb; 20(1):1-10. PubMed ID: 31784932
[TBL] [Abstract][Full Text] [Related]
2. Platelet Signaling Pathways and New Inhibitors.
Grover SP; Bergmeier W; Mackman N
Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):e28-e35. PubMed ID: 29563117
[No Abstract] [Full Text] [Related]
3. Platelet biology and functions: new concepts and clinical perspectives.
van der Meijden PEJ; Heemskerk JWM
Nat Rev Cardiol; 2019 Mar; 16(3):166-179. PubMed ID: 30429532
[TBL] [Abstract][Full Text] [Related]
4. Platelet oxidative stress as a novel target of cardiovascular risk in frail older people.
Fuentes F; Palomo I; Fuentes E
Vascul Pharmacol; 2017 Aug; 93-95():14-19. PubMed ID: 28705733
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention.
Sepúlveda C; Palomo I; Fuentes E
Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822
[TBL] [Abstract][Full Text] [Related]
6. Esculetin, a Coumarin Derivative, Prevents Thrombosis: Inhibitory Signaling on PLCγ2-PKC-AKT Activation in Human Platelets.
Hsia CW; Lin KC; Lee TY; Hsia CH; Chou DS; Jayakumar T; Velusamy M; Chang CC; Sheu JR
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31163690
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of platelet activation-inhibitory drugs.
Rao GH; Rao AT
Indian J Physiol Pharmacol; 1994 Apr; 38(2):69-84. PubMed ID: 8063366
[TBL] [Abstract][Full Text] [Related]
8. Gintonin modulates platelet function and inhibits thrombus formation via impaired glycoprotein VI signaling.
Irfan M; Jeong D; Saba E; Kwon HW; Shin JH; Jeon BR; Kim S; Kim SD; Lee DH; Nah SY; Rhee MH
Platelets; 2019; 30(5):589-598. PubMed ID: 29870296
[TBL] [Abstract][Full Text] [Related]
9. The effects of ginsenosides on platelet aggregation and vascular intima in the treatment of cardiovascular diseases: From molecular mechanisms to clinical applications.
Luo BY; Jiang JL; Fang YF; Yang F; Yin MD; Zhang BC; Zhao RR; Shao JW
Pharmacol Res; 2020 Sep; 159():105031. PubMed ID: 32562816
[TBL] [Abstract][Full Text] [Related]
10. Novel Antiplatelet Agents in Cardiovascular Disease.
Tscharre M; Michelson AD; Gremmel T
J Cardiovasc Pharmacol Ther; 2020 May; 25(3):191-200. PubMed ID: 31960728
[TBL] [Abstract][Full Text] [Related]
11. The Role of Platelets in Cardiovascular Disease: Molecular Mechanisms.
Papapanagiotou A; Daskalakis G; Siasos G; Gargalionis A; Papavassiliou AG
Curr Pharm Des; 2016; 22(29):4493-4505. PubMed ID: 27281334
[TBL] [Abstract][Full Text] [Related]
12. Possible Molecular Targets of Novel Ruthenium Complexes in Antiplatelet Therapy.
Jayakumar T; Hsu CY; Khamrang T; Hsia CH; Hsia CW; Manubolu M; Sheu JR
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29925802
[TBL] [Abstract][Full Text] [Related]
13. Association between microvesicles bearing monomeric C-reactive protein and platelet reactivity. Relationship with low response to antiplatelet drugs?
Siennicka A
J Physiol Pharmacol; 2021 Feb; 72(1):. PubMed ID: 34099580
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibition of platelet reactivity. Clinical and pharmacodynamic effects.
Vallés J; Moscardo A; Madrid I; Santos MT
Curr Vasc Pharmacol; 2013 Jul; 11(4):431-47. PubMed ID: 23905638
[TBL] [Abstract][Full Text] [Related]
15. CD40L Priming of Platelets via NF-κB Activation is CD40- and TAK1-Dependent.
Kojok K; Akoum SE; Mohsen M; Mourad W; Merhi Y
J Am Heart Assoc; 2018 Dec; 7(23):e03677. PubMed ID: 30571597
[TBL] [Abstract][Full Text] [Related]
16. Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.
Yeung J; Li W; Holinstat M
Pharmacol Rev; 2018 Jul; 70(3):526-548. PubMed ID: 29925522
[TBL] [Abstract][Full Text] [Related]
17. Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: A step from inflammation to thrombosis.
Alvarez A; Rios-Navarro C; Blanch-Ruiz MA; Collado-Diaz V; Andujar I; Martinez-Cuesta MA; Orden S; Esplugues JV
Antiviral Res; 2017 May; 141():179-185. PubMed ID: 28263802
[TBL] [Abstract][Full Text] [Related]
18. Regulation of Key Antiplatelet Pathways by Bioactive Compounds with Minimal Bleeding Risk.
Fuentes E; Wehinger S; Trostchansky A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830261
[TBL] [Abstract][Full Text] [Related]
19. Platelets, inflammation and anti-inflammatory effects of antiplatelet drugs in ACS and CAD.
Müller KA; Chatterjee M; Rath D; Geisler T
Thromb Haemost; 2015 Aug; 114(3):498-518. PubMed ID: 26224127
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
Jennings LK
Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
